On May 4, 2026 Iterion Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for Wnt/β-catenin-driven cancers, reported that tegavivint, a first-in-class small-molecule inhibitor of TBL1, will be featured in three presentations at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29–June 2 in Chicago.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Headlining Iterion’s presence is a rapid oral abstract session presenting Phase 1/2 dose-finding data in advanced hepatocellular carcinoma (HCC), which is the third-leading cause of cancer death globally and an area where treatment options remain limited.
"Advanced HCC is a devastating cancer with limited treatment options, and for the approximately half of patients whose tumors harbor activating mutations in the Wnt/β-catenin pathway, there are currently no approved targeted therapies directed at this biology," said Rahul Aras, Ph.D., President and CEO of Iterion Therapeutics. "Tegavivint was specifically designed to address this urgent unmet need. By disrupting the TBL1–β-catenin transcriptional complex, it offers a highly differentiated mechanism that promotes nuclear β-catenin degradation and inhibits β-catenin driven oncogenic transcription. Selection of our dose-finding data for a rapid oral abstract session, alongside investigator-sponsored studies in NSCLC and pediatric osteosarcoma, reflects growing scientific interest in TBL1 as a druggable target across Wnt-driven cancers."
The ASCO (Free ASCO Whitepaper) presentations follow a series of recent milestones for Iterion, including dosing the first patients in clinical trials in metastatic colorectal cancer and relapsed/refractory pediatric osteosarcoma, as well as the presentation of new preclinical data earlier this year at AACR (Free AACR Whitepaper) supporting TBL1 as a druggable therapeutic target.
ASCO 2026 Presentation Details
Oral Presentation – Advanced Hepatocellular Carcinoma
Abstract #
4015
Title
Tegavivint, a downstream Wnt/β-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC)
Session
Rapid Oral Abstract Session – Gastrointestinal Cancer (Gastroesophageal, Pancreatic, and Hepatobiliary)
Date/Time
June 1, 2026 | 1:15-2:45 PM CDT
Poster Presentation – Metastatic EGFR-Mutated NSCLC
Title
A phase Ib study of osimertinib and tegavivint as first-line therapy in patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC)
Session
Poster Session – Lung Cancer-Non-Small Cell Metastatic
Poster Board
438
Date/Time
May 31, 2026 | 9:00 AM-12:00 PM CDT
Poster Presentation – Relapsed or Refractory Osteosarcoma
Title
A phase 1b study of tegavivint, a TBL1 inhibitor, with gemcitabine in patients with relapsed or refractory osteosarcoma (TIGER)
Session
Poster Session – Sarcoma
Poster Board
376a
Date/Time
June 1, 2026 | 1:30-4:30 PM CDT
About Tegavivint
Tegavivint is a first-in-class small-molecule inhibitor of TBL1, a critical transcriptional regulator required for nuclear β-catenin stability and oncogenic gene expression. By disrupting the TBL1–β-catenin transcriptional complex, tegavivint promotes degradation of nuclear β-catenin, inhibits oncogenic transcriptional programs driven by Wnt signaling, and has demonstrated potent anti-tumor activity in preclinical models and clinical studies. Tegavivint is currently being evaluated in a Phase 1/2 clinical trial in advanced HCC and in investigator-sponsored studies in metastatic CRC, EGFR-mutated non-small cell lung cancer, and relapsed or refractory pediatric osteosarcoma.
(Press release, Iterion Therapeutics, MAY 4, 2026, View Source [SID1234665049])